Oesterling J E, Martin S K, Bergstralh E J, Lowe F C
Department of Urology, Mayo Clinic, Rochester, MN 55905.
JAMA. 1993 Jan 6;269(1):57-60.
To assess the need for obtaining radionuclide bone scans in the staging evaluation of patients with newly diagnosed, untreated prostate cancer. This determination was made on the basis of presenting prostate-specific antigen (PSA) levels.
Retrospective review.
The medical records of 2064 consecutive patients with prostate cancer who were evaluated at the Mayo Clinic in Rochester, Minn, from January 1989 through December 1990 were reviewed. Eight hundred fifty-two patients with newly diagnosed, untreated disease and a serum PSA concentration less than 20.0 micrograms/L at presentation comprised the study population.
The rate of false-negative results associated with using the serum PSA concentration to predict bone scan findings.
Five hundred sixty-one patients had a serum PSA concentration of 10.0 micrograms/L or less; only three had an abnormal bone scan result, and one had an indeterminate scan result. Of the 467 men whose PSA value was 8.0 micrograms/L or less (two times the upper limit of the reference range), none had bone scan results that were either abnormal or indeterminate. The rate of false-negative results for an abnormal bone scan result was 0% with a serum PSA value of 8.0 micrograms/L or less and 0.5% with a cutoff level of 10.0 micrograms/L. The 95% upper confidence limit for the rate of false-negative results for all PSA cutoff levels less than 20.0 micrograms/L was less than 2%.
For patients with newly diagnosed, untreated prostate cancer, a serum PSA concentration of 10.0 micrograms/L or less, and no skeletal symptoms, a staging radionuclide bone scan does not appear to be necessary. This clinical situation applies to 39% of all patients presenting with newly diagnosed prostate cancer. Since more than 130,000 new cases are diagnosed each year, approximately 50,000 patients are affected annually. If the $600 staging bone scan were eliminated for these patients, a significant economic savings to the health care system in this country would be effected.
评估在新诊断、未经治疗的前列腺癌患者分期评估中进行放射性核素骨扫描的必要性。这一判定基于患者就诊时的前列腺特异性抗原(PSA)水平。
回顾性研究。
回顾了1989年1月至1990年12月在明尼苏达州罗切斯特市梅奥诊所接受评估的2064例连续前列腺癌患者的病历。852例新诊断、未经治疗且就诊时血清PSA浓度低于20.0微克/升的患者组成了研究人群。
使用血清PSA浓度预测骨扫描结果时假阴性结果的发生率。
561例患者血清PSA浓度为10.0微克/升或更低;只有3例骨扫描结果异常,1例扫描结果不确定。在467例PSA值为8.0微克/升或更低(两倍参考范围上限)的男性中,无人的骨扫描结果异常或不确定。血清PSA值为8.0微克/升或更低时,骨扫描结果异常的假阴性结果发生率为0%,临界值为10.0微克/升时为0.5%。所有低于20.0微克/升的PSA临界值的假阴性结果发生率的95%置信上限低于2%。
对于新诊断、未经治疗且血清PSA浓度为10.0微克/升或更低且无骨骼症状的前列腺癌患者,似乎无需进行分期放射性核素骨扫描。这种临床情况适用于所有新诊断前列腺癌患者中的39%。由于每年有超过130000例新病例被诊断,每年约有50000名患者受影响。如果为这些患者省去600美元的分期骨扫描,将为该国医疗保健系统节省大量资金。